Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 11/20 | 0.49 |
| ▸ | RHOC | P08134 | 4/20 | 0.44 |
| ▸ | RHOA | P61586 | 4/20 | 0.44 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 4/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7684256 | 0.89 | TACR1 (0.55) | TACR1RHOCRHOATACR3OPRK1 | |
| SCHEMBL12809194 | 0.87 | OPRK1 (0.52) | TACR1RHOCRHOATACR3OPRK1 | |
| SCHEMBL730772 | 0.86 | TACR1 (0.66) | TACR1RHOCRHOATACR3USP2 | |
| SCHEMBL4987212 | 0.86 | TACR1 (0.49) | TACR1RHOCRHOATACR3OPRK1 | |
| SCHEMBL4987525 | 0.85 | TACR1 (0.48) | TACR1RHOCRHOATACR3USP2 | |
| SCHEMBL7864817 | 0.84 | TACR1 (0.48) | TACR1 | |
| Hydrochloric Acid SCHEMBL5369403 | 0.80 | L3MBTL1 (0.49) | TACR1RHOCRHOA | |
| SCHEMBL15358923 | 0.78 | NR1H2 (0.40) | OPRK1 | |
| SCHEMBL5372143 | 0.77 | TACR1 (0.55) | TACR1USP2CYP2D6CYP3A4 | |
| SCHEMBL4983555 | 0.75 | TACR1 (0.62) | TACR1RHOCRHOATACR3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6346540-B1 | SUBSTANCE P ANTAGONISTS FOR TREATING CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL AND BRAIN DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-02-12 | — | — | US | disclosed |
| EP-0843679-B1 | 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-(FUSED IMIDAZOLE)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2001-11-07 | — | — | EP | disclosed |
| EP-0855999-B1 | 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2001-10-04 | — | — | EP | disclosed |
| US-6251894-B1 | SUBSTANCE P ANTAGONISTS | JANSSEN PHARMACEUTICALS N.V. (BE) | 2001-06-26 | — | — | US | disclosed |
| US-6169097-B1 | 1-(1,2-Disubstituted piperidinyl)-4-substituted piperidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-02 | — | — | US | disclosed |
| EP-0855999-A1 | 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-08-05 | — | — | EP | disclosed |
| EP-0843679-A1 | 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-(FUSED IMIDAZOLE)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-05-27 | — | — | EP | disclosed |
| WO-1997024324-A1 | 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997024356-A1 | 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-(FUSED IMIDAZOLE)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-07-10 | — | — | WO | disclosed |